Exact Sciences

Exact Sciences has received all required regulatory approvals for its planned merger with Abbott; the transaction is expected to close on March 23, 2026, subject to final contractual conditions. Shareholders had already approved the takeover, and the stock is trading near its 52‑week high, reflecting the merger premium. Mizuho downgraded the stock from "Outperform" to "Neutral" following the deal but raised the price target to $105.00. The board pre‑approved accelerated bonuses and equity awards for executives to mitigate tax dislocations from the transaction, and the merger comes amid proposed legislation to have Medicare cover early detection tests. » More on de.investing.com

Shareholders of Exact Sciences approved the November 19, 2025 merger agreement to combine the company with Abbott, while an advisory vote on executive compensation tied to the deal was not approved. Management said it expects the transaction to close before the end of Q2 2026 subject to required regulatory approvals and noted ongoing merger-related litigation disclosed in SEC filings. Final vote tallies will be included in the inspector’s report and filed on a Form 8-K within four business days. » More on finance.yahoo.com

Exact Sciences shareholders voted at a special general meeting to approve a merger with a subsidiary of Abbott Laboratories, which would make Exact Sciences a wholly owned subsidiary of Abbott. Of 190,810,202 voting shares eligible, 128,906,310 were represented; the merger proposal received 128,431,562 votes in favor, with 386,941 against and 87,807 abstentions. The transaction contemplates an all-cash takeover at $105 per share (equity value about $21 billion) and remains subject to customary closing conditions, including regulatory approvals; a non-binding proposal on executive compensation was rejected. » More on de.investing.com